Profit after tax climbed to £5.7 billion ($7.8 billion) compared with profit of £2.6 billion in 2024, GSK said in a statement. “GSK delivered another strong performance in 2025, driven mainly by Speciality Medicines,” said chief executive Luke Miels, who took over from Emma Walmsley at the start of the year. GSK forecasts a low double-digit increase in revenue for its speciality medicines this year, but it expects revenue from vaccines and general medicines to decline. GSK, along with several other pharmaceutical giants, agreed in December to lower the cost of its prescription medicines for American patients, in exchange for tariff exemptions for three years. The United States accounted for more than half of GSK’s total revenues last year.

Source: Punch February 04, 2026 09:44 UTC